R&D investment exceeds RMB 100 million! A approved clinical trial of the new drug intended to be used in the treatment of alopecia areata by Reistone Biopharma

 



Hengrui Medicine (600276) announced in the evening that Reistone Biopharma Company Limited, a subsidiary of the company, recently received the Notice of Clinical Trial approved and issued by NMPA. According to the notice, after review, SHR0302 tablets accepted by NMPA on November 12, 2019 comply with the relevant requirements of drug registration, and it is agreed to carry out the clinical trial of this product to be used for alopecia areata according to the submitted protocol.


On November 12, 2019, the clinical trial application submitted by Reistone Biopharma Company Limited to the NMPA was accepted. SHR0302 is a small-molecule JAK1 kinase selective inhibitor and is intended to be used in the treatment of alopecia areata. 


Upon inquiry, no JAK inhibitor has been approved for the treatment of alopecia areata at home and abroad. At present, many JAK inhibitors have been clinically studied for alopecia areata indications all over the world, among which the Baricitinib of Eli Lilly and Company and PF-06651600 of Pfizer have entered the phase III clinical trial stage. Up to now, the R&D cost of SHR0302 project is about RMB 115.9 million.
SHR0302 is a selective JAK1 inhibitor, which is an innovative chemical drug independently developed by China. At present, Reistone is developing SHR0302 for inflammatory bowel disease (IBD), such as ulcerative colitis (UC), Crohn's disease (CD) and skin diseases (such as atopic dermatitis) all over the world. 


Reistone Biopharma is a global biopharma company focused on the development of new drugs. The headquarter is established in Zhangjiang, Shanghai, with offices in Beijing and Boston, which was invested and established by Jiangsu Hengrui Medicine Co., Ltd, the largest innovative drug company in China. 


Editor: Meng Qing
Executive editor: Deng Yimeng
Source: Drug News



Date of issue:2020-02-21 00:00
Share to:
Read more articles